Product category:
Miscellaneous Instruments
News Release from: LGC
Edited by the Manufacturingtalk Editorial
Team on 15 December 2004
DNA probe technology licensed by
Osmetech
LGC,has signed an exclusive agreement for licensing its DNA probe technology with Osmetech in medical genetic test applications for inherited genetic traits in all world markets, excluding India.
LGC, has signed an exclusive agreement for licensing its DNA probe technology (HyBeacons) with Osmetech in medical genetic test applications for inherited genetic traits in all world markets, excluding India HyBeacons have unique characteristics that make them suitable for very rapid diagnostic and point-of-care applications
This article was originally published on Manufacturingtalk on 10 Mar 2003 at 8.00am (UK)
Related stories
LGC Launches ADME-Tox Screening Service
Bioanalytical services at LGC's new ADME-Tox laboratory include in vitro drug metabolism, cellular toxicology and prediction of gastrointestinal transport.
Phytochemical Reference Standards Now Available
Over 2500 high purity ChromaDex phytochemical - or herbal - reference standards are now available exclusively from LGC Promochem throughout Europe.
Osmetech, the international diagnostics business, will use the HyBeacon technology with its Genedrive molecular diagnostics instrument and other platforms.
Osmetech has been working closely with LGC for approximately one year, during which time scientific proof of principle has been established demonstrating the excellent compatibility of HyBeacon tests with the Genedrive.
Although the majority of molecular diagnostic testing is currently performed in batches in larger hospitals and laboratories, the growth in molecular diagnostics is expected to be most evident in small to medium sized hospitals now looking to perform much of this testing in-house.
Further reading
Partnership Makes Inorganic Standards Available
Over 450 ULTRA Scientific inorganic reference standards are now available for immediate delivery to European end users from LGC Promochem.
Regulatory Atlas - Overview of Biotechnology
The new Biotechnology Regulatory Atlas - compiled by LGC for the Department of Trade and Industry (DTI) - guides SMEs and start-up companies on effective compliance strategies.
New USP Standards 100 Seminar Dates Announced
Specialist training in the use of USP-NF (the United States Pharmacopoeia and National Formulary) is being provided in two seminars during October 2003 organised by LGC Promochem.
This is the setting in which it is envisaged that the Genedrive-HyBeacon device will be targeted.
James White, Chief Executive, Osmetech plc said: "We are delighted to be working with LGC and its HyBeacon technology, which will provide us with the chemistry for our instrument platform".
" The Genedrive uses well understood and widely adopted PCR-based technology to produce a simple, cost-effective and rapid test with the key performance characteristics of the fast growing molecular diagnostics market".
" Osmetech's OPTI business already has the operational structure, distributor network and customer base necessary to exploit these exciting growth opportunities." Discussions for LGC to grant similar licences for the detection of infectious human pathogens and diagnosis of human sexually transmitted diseases are also at an advanced stage with Osmetech.
A recent study of clinical samples has been completed at the medical microbiology department of the Royal Free Hospital in London to evaluate the HyBeacon chlamydia detection assay run on the Genedrive instrument.
Although this study was not optimised or performed under FDA clinical trial guidelines, the results exhibited a high degree of accuracy in comparison with other widely practised nucleic acid amplification tests.
Dr Paul Debenham, LGC's Director of Life Sciences, said: "LGC continues to advance its genetic test HyBeacon technology, developed with DTI support under the LINK Analytical Biotechnology programme, across the spectrum of applications for which rapid point-of-care testing is in demand".
" We are excited to see HyBeacons being put into use by Osmetech for this first licence in medical diagnostic applications".
" We are looking forward to its ongoing development and our collaboration with Osmetech in identifying new testing capabilities." LGC was advised on the licence agreement by its in-house legal team and by John Wilkinson and Shirley McCulloch of international law firm, Bird and Bird.
Mark Lubbock and Jonathan Lewin of international law firm, Ashurst, advised Osmetech.
• LGC: contact details and other news
• Email this article to a colleague
• Register for the free Manufacturingtalk email newsletter
• Manufacturingtalk Home Page
Search the Pro-Talk network of sites
